347,03 €
385,59 €
-10% with code: EXTRA
Fluoropyrimidines in Cancer Therapy
Fluoropyrimidines in Cancer Therapy
347,03
385,59 €
  • We will send in 10–14 business days.
Leading cancer researchers update and review the mechanisms of action and the therapeutic selectivity and efficacy of 5-FU with and without leucovorin and its prodrugs in the treatment of colorectal cancer. Among the combination agents considered are UFT/LV, 5-FU/EU, capecitabine (Xeloda), S-1, and a variety of thymidylate synthase inhibitors. The authors discuss the potential advantages and disadvantages of these varied drugs and their mode of administration. Based on historical results with t…
  • Publisher:
  • ISBN-10: 0896039560
  • ISBN-13: 9780896039568
  • Format: 17.8 x 25.4 x 2.1 cm, hardcover
  • Language: English
  • SAVE -10% with code: EXTRA

Fluoropyrimidines in Cancer Therapy (e-book) (used book) | bookbook.eu

Reviews

Description

Leading cancer researchers update and review the mechanisms of action and the therapeutic selectivity and efficacy of 5-FU with and without leucovorin and its prodrugs in the treatment of colorectal cancer. Among the combination agents considered are UFT/LV, 5-FU/EU, capecitabine (Xeloda), S-1, and a variety of thymidylate synthase inhibitors. The authors discuss the potential advantages and disadvantages of these varied drugs and their mode of administration. Based on historical results with these agents when used alone, they also present a rationale for their results when used in combination with other agents.

EXTRA 10 % discount with code: EXTRA

347,03
385,59 €
We will send in 10–14 business days.

The promotion ends in 18d.11:19:03

The discount code is valid when purchasing from 10 €. Discounts do not stack.

Log in and for this item
you will receive 3,86 Book Euros!?
  • Publisher:
  • ISBN-10: 0896039560
  • ISBN-13: 9780896039568
  • Format: 17.8 x 25.4 x 2.1 cm, hardcover
  • Language: English English

Leading cancer researchers update and review the mechanisms of action and the therapeutic selectivity and efficacy of 5-FU with and without leucovorin and its prodrugs in the treatment of colorectal cancer. Among the combination agents considered are UFT/LV, 5-FU/EU, capecitabine (Xeloda), S-1, and a variety of thymidylate synthase inhibitors. The authors discuss the potential advantages and disadvantages of these varied drugs and their mode of administration. Based on historical results with these agents when used alone, they also present a rationale for their results when used in combination with other agents.

Reviews

  • No reviews
0 customers have rated this item.
5
0%
4
0%
3
0%
2
0%
1
0%
(will not be displayed)